Eli Lilly enters into strategic partnership on metabolic diseases with Regor Therapeutics

Novo Nordisk competitor Eli Lilly has announced a collaboration with Regor Therapeutics within metabolic diseases such as diabetes and obesity.

Photo: Vincent Kessler/Reuters/Ritzau Scanpix

US-based Eli Lilly and Regor Therapeutics Group have entered into a development collaboration and licensing agreement to discover, develop and commercialize new therapies within metabolic diseases like diabetes and obesity.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs